Ptc Therapeutics (PTCT) Amortization of Deferred Charges (2015 - 2026)

Ptc Therapeutics' Amortization of Deferred Charges history runs 12 years deep, the most recent figure standing at $265000.0 for Q2 2026.

• In Q2 2026, Amortization of Deferred Charges fell 11.96% year-over-year to $265000.0; the TTM figure through Jun 2026 stood at $4.2 million (up 7.57% YoY), while the FY2025 annual figure was $7.5 million, down 3.68% from the prior year.
• Amortization of Deferred Charges for Q2 2026 stood at $265000.0, down from $1.8 million in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $2.9 million in Q1 2023, with the low at $265000.0 in Q2 2026.
• The 5-year median for Amortization of Deferred Charges is $893000.0 (2024), against an average of $1.1 million.
• The sharpest annual moves came in 2023 and 2024: Amortization of Deferred Charges soared 54.19% in 2023, then slumped 39.09% in 2024.
• Ptc Therapeutics' Amortization of Deferred Charges stood at $2.4 million in 2022, then slipped by 29.76% to $1.7 million in 2023, then dropped by 11.43% to $1.5 million in 2024, then advanced by 23.78% to $1.8 million in 2025, then slumped by 85.53% to $265000.0 in 2026.
• Business Quant data shows PTCT's Amortization of Deferred Charges at $265000.0 in Q2 2026, $1.8 million in Q1 2026, and $1.8 million in Q4 2025.